

| Notation             | Parameter                                                      | Value                               |
|----------------------|----------------------------------------------------------------|-------------------------------------|
|                      | <i>Age progression rate</i> <sup>a</sup>                       |                                     |
| $\alpha_1$           | Group 1 [18-27]                                                | 1/9/365 <i>day</i> <sup>-1</sup>    |
| $\alpha_2$           | Group 2 [27-33]                                                | 1/6/365 <i>day</i> <sup>-1</sup>    |
| $\alpha_3$           | Group 3 [33-40]                                                | 1/7/365 <i>day</i> <sup>-1</sup>    |
| $\alpha_4$           | Group 4 [40-80.5)                                              | 1/40.5/365 <i>day</i> <sup>-1</sup> |
|                      | <i>Stage progression rate</i> <sup>b</sup>                     |                                     |
| $\gamma_1$           | Stage 1 (early HIV infection)                                  | 1/0.5/365 <i>day</i> <sup>-1</sup>  |
| $\gamma_2$           | Stage 2 (CD4 > 500 cells/mm3)                                  | 1/3.32/365 <i>day</i> <sup>-1</sup> |
| $\gamma_3$           | Stage 3 (350 < CD4 ≤ 500 cells/mm3)                            | 1/2.7/365 <i>day</i> <sup>-1</sup>  |
| $\gamma_4$           | Stage 4 (200 < CD4 ≤ 350 cells/mm3)                            | 1/5.5/365 <i>day</i> <sup>-1</sup>  |
| $\gamma_5$           | Stage 5 (CD4 ≤ 200 cells/mm3)                                  | 1/5.06/365 <i>day</i> <sup>-1</sup> |
|                      | <i>Fraction of individuals transitioning from</i> <sup>b</sup> |                                     |
| $\pi_1$              | Stage 1 to stage 2                                             | 0.76                                |
| $\pi_2$              | Stage 1 to stage 3                                             | 0.19                                |
| $\pi_3$              | Stage 1 to stage 4                                             | 0.05                                |
| $\pi_4$              | Stage 1 to stage 5                                             | 0                                   |
| $a$                  | Age assortativity factor                                       | 0.5                                 |
| $p$                  | Proportion of individuals in low-risk group                    | 0.8                                 |
| $m$                  | Per lineage rate of migration to source compartment            | 1/50/365 <i>day</i> <sup>-1</sup>   |
| $g$                  | Rate of growth of source compartment                           | 1/3/365 <i>day</i> <sup>-1</sup>    |
| $s$                  | Initial size of source compartment                             | 1000                                |
| $i$                  | Incidence scaling factor for London MSM <sup>c</sup>           | 0.03                                |
|                      | <i>Diagnosis rate</i>                                          |                                     |
| $d_{85}$             | Fixed rate prior to 1985                                       | 1/10 <i>year</i> <sup>-1</sup>      |
| $\mu_d$              | Maximum value of logistic function after 1985 <sup>c</sup>     | 1/3 <i>year</i> <sup>-1</sup>       |
| $k_d$                | Steepness of logistic function after 1985 <sup>c</sup>         | 1/7 <i>year</i> <sup>-1</sup>       |
|                      | <i>Treatment rate</i>                                          |                                     |
| $t_{95}$             | Fixed rate prior to 1995                                       | 0                                   |
| $\mu_t$              | Maximum value of logistic function after 1995                  | 1                                   |
| $k_t$                | Steepness of logistic function after 1995                      | 0.5                                 |
| $e$                  | Treatment effectiveness                                        | 0.95                                |
|                      | <i>Transmission weight conferred to individuals in</i>         |                                     |
| $w_{s1}$             | Stage 1                                                        | 1                                   |
| $w_{s2}$ to $w_{s4}$ | Stages 2 to 4                                                  | 0.1                                 |
| $w_{s5}$             | Stage 5                                                        | 0.3                                 |
| $w_{a1}$ to $w_{a4}$ | Age groups 1 to 4                                              | 1                                   |
| $w_{c1}$             | Care status 1 (undiagnosed)                                    | 1                                   |
| $w_{c2}$             | Care status 2 (diagnosed and untreated)                        | 0.5                                 |
| $w_{c3}$             | Care status 3 (diagnosed and treated)                          | 0.05                                |
| $w_{r1}$             | Risk status 1 (low risk)                                       | 1                                   |
| $w_{r2}$             | Risk status 2 (high risk)                                      | 10                                  |

<sup>a</sup> From quartiles of age of MSM diagnosed in London available in UKDRDB

<sup>b</sup> From Cori et al. AIDS 2015

<sup>c</sup> Initial value later calibrated to retrieve observed number of diagnosed cases from surveillance data